Literature DB >> 3941559

Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung.

W P Luke, F G Pearson, T R Todd, G A Patterson, J D Cooper.   

Abstract

Between 1979 and 1984, mediastinoscopy was performed on 1,000 of the 1,500 patients admitted to the Thoracic Surgical Service of the Toronto General Hospital with the diagnosis of carcinoma of the lung. In 144 cases, concomitant anterior mediastinoscopy was also performed. Abnormal mediastinal nodes were found in 296 (29.6%). The overall complication rate was 2.3%, with no deaths. Mediastinoscopy revealed diseased nodes in 24% of patients with squamous cell carcinoma, 29% with adenocarcinoma, 54% with small cell undifferentiated carcinoma, 31% with large cell undifferentiated carcinoma, and 12% with bronchoalveolar carcinoma. Abnormal mediastinal nodes were found with equal frequency in right- and left-sided tumors and occurred in 31% of tumors in the main bronchus, 25% of upper lobe tumors, and 17% of lower lobe tumors. Of the 704 patients having negative results of mediastinoscopy, 590 were subjected to thoracotomy. Ninety-three percent underwent resection (85% curative, 7% palliative) and 7% had unresectable tumors. Of the resections, 20% were pneumonectomies. At thoracotomy, 52 of the 590 patients with negative mediastinoscopic results were found to have abnormal mediastinal nodes. Sixty-two of the 296 patients with positive results of mediastinoscopy were selected for thoracotomy. Eighty-six percent had resectable lesions (67% curative, 18% palliative) and 14% unresectable. The pneumonectomy rate in this group was 35%. These current data support our previous opinion that routine mediastinoscopy can be done with negligible morbidity and provides essential information for the classification and management of cancer of the lung.

Entities:  

Mesh:

Year:  1986        PMID: 3941559

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  24 in total

1.  The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer.

Authors:  G M Tsang; D C Watson
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

Review 2.  Progress in lung cancer: non-oat cell (non-small cell lung cancer).

Authors:  E J Beattie; N M Raskin
Journal:  Jpn J Surg       Date:  1987-09

3.  The 7th lung cancer TNM classification and staging system: Review of the changes and implications.

Authors:  Saeed Mirsadraee; Dilip Oswal; Yalda Alizadeh; Andrea Caulo; Edwin van Beek
Journal:  World J Radiol       Date:  2012-04-28

4.  Mediastinal lymph node metastases in lung cancer: is size a valid criterion?

Authors:  D K Kaplan
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

5.  Mediastinoscopy as a predictor of resectability in patients with bronchogenic carcinoma.

Authors:  D S Ríordáin; D J Buckley; T Aherne
Journal:  Ir J Med Sci       Date:  1991-09       Impact factor: 1.568

6.  Successful management of severe pulmonary artery injury during mediastinoscopy.

Authors:  Takeshi Nagayasu; Tsutomu Tagawa; Naoya Yamasaki; Tomoshi Tsuchiya; Takuro Miyazaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-01-12

7.  The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer.

Authors:  H Osada; Y Nakajima; Y Taira; K Yokote; T Noguchi
Journal:  Jpn J Surg       Date:  1987-09

Review 8.  The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer.

Authors:  Katarzyna Czarnecka-Kujawa; Kazuhiro Yasufuku
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

9.  Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes.

Authors:  F J F Herth; R Eberhardt; P Vilmann; M Krasnik; A Ernst
Journal:  Thorax       Date:  2006-05-31       Impact factor: 9.139

10.  Mediastinoscopy: trends and practice patterns in the United States.

Authors:  Krishna S Vyas; Daniel L Davenport; Victor A Ferraris; Sibu P Saha
Journal:  South Med J       Date:  2013-10       Impact factor: 0.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.